The Future of Clinical Trials: A Shift from Artificial to Augmented to Applied Intelligence

By Staff Writer

December 20, 2023

The Present Situation Regarding Clinical Trials

Clinical trials, the bedrock of medical advancements, must embrace significant innovation. With global spending on these trials exceeding $50 billion now and predicted to reach over $85 billion by 2030, we must question the value we’re getting from this rapidly growing industry. What is the role of Artificial intelligence (AI) in clinical trials?  There are frequently chances to address chronic health disorders that are hampered by the time and costs associated with major trials. Despite the fact that there is a clear demand for improved evidence that is supplied in a more expedient manner through clinical trials that are efficient, the fundamental costs of the majority of clinical trials have not changed.

The Role of Artificial Intelligence in Clinical Trials

AI is reshaping both scientific research and medical practice. AI holds immense potential to transform clinical research, from improving human judgement to automating tasks. Manual transfer and verification of data account for a significant portion of clinical trial costs. These processes are ripe for automation. Therefore, the breakthrough in clinical trials likely requires the integration of AI. 

Natural Language Processing in Clinical Trials

In a recent study, authors investigated if Natural Language Processing (NLP) models could effectively classify heart failure hospitalisations. They found a high agreement level between the NLP model and the trial-adjudicated case outcomes. This finding suggests that using AI for event adjudication could save significant time and costs. However, they have not yet identified the requirements for calibration, validation, and periodic performance assessment during the scaling process.

The Prospects for Artificial Intelligence in Clinical Trials

AI can significantly improve the development, execution, and dissemination of clinical trials. It can enhance efficiency and remove bias in areas like participant identification, study procedure generation, and trial material production. However, we need an oversight structure to ensure the trials don’t incorporate previous biases. By addressing the risks properly, we can safely and ethically realise the benefits of artificial intelligence in clinical trials. 

In conclusion, recent studies show that AI-enhanced clinical research is achievable and potentially beneficial. As we learn more, we must find ways to honestly communicate our limitations and failures without damaging the process’s integrity. High-quality evaluations of AI tools, using rigorous designs and analysis, are crucial to provide quality information about the benefits and risks of using AI in clinical trials. We need these kinds of publications to support the research behind AI-enhanced clinical trials and maintain trust in AI applications for these trials. 

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.